INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 200 | -- | 2,048 |
Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 1,400 | -- | 648 |
Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 200 | -- | 448 |
Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 400 | -- | 48 |
Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 48 | -- | -- |
Oct 31, 2006 |
SVP, Therap & Clin Prog Dev
|
SVP, Therap & Clin Prog Dev | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 18,311 | -- | -- |
Dec 17, 2008 |
SVP, Research & Devel Sciences
|
SVP, Research & Devel Sciences | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,952 | -- | 5,952 |
Dec 17, 2008 |
SVP, Research & Devel Sciences
|
SVP, Research & Devel Sciences | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 44,048 | -- | 44,048 |
Oct 01, 2008 |
SVP, Research & Devel Sciences
|
SVP, Research & Devel Sciences | Form 4 | Other acquisition or disposition | -- | -- | 4,275 |
Sep 30, 2008 |
SVP, Research & Devel Sciences
|
SVP, Research & Devel Sciences | Form 4 | Open market or private sale of non-derivative or derivative security | 200 | $21.66 | 10,467 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.